Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.
Read more about ipilimumab, nivolumab, and other immunotherapies being looked at in melanoma > >
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More